CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT, AS AMENDED. OMNIBUS AMENDMENT TO...Omnibus Amendment to Zevalin Supply Arrangements • November 9th, 2012 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This Omnibus Amendment to Zevalin Supply Arrangements (this “Amendment”) is made effective as of the 1st day of October, 2012 by and between Biogen Idec US Corporation, a Massachusetts corporation (“Biogen Idec”), on one hand, and RIT Oncology, LLC, a Delaware limited liability company and wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. (“RIT”), and Spectrum Pharmaceuticals Cayman, L.P., a Cayman exempted limited partnership and wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. (“Cayman”) (RIT and Cayman, collectively, “Spectrum”), on the other hand. Biogen Idec and Spectrum are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
